Roche Ramps Up Breast Cancer Pipeline With Regor's CDK …
WEB9 hours ago · Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of...
Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB1 day ago · Regor Pharmaceuticals (USA) ("Regor") has entered into a definitive purchase agreement whereby Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK...
Genentech inks $850M upfront deal for Regor's CDK inhibitors
WEB1 day ago · Genentech’s acquisition of the Regor portfolio, which is expected to close in the fourth quarter, will give Roche its own CDK inhibitors. After selling the CDK inhibitor portfolio, Regor will...
Genentech buys Regor’s CDK inhibitors in $850m deal - Yahoo …
WEB8 hours ago · ROG.SW. Genentech is strengthening its oncology pipeline by acquiring Regor Pharmaceuticals’ portfolio of breast cancer cyclin-dependent kinase (CDK) inhibitors in an $850m deal. The deal,...
Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB1 day ago · Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on...
Genentech buys Regor's next-gen CDK inhibitors for $850M
WEB1 day ago · Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash...
Roche Doubles Down on Breast Cancer With $850M for Regor’s …
WEB1 day ago · A portfolio of CDK inhibitors developed by Regor Pharmaceuticals has found a home at Roche, which announced Monday it would buy the investigational cancer drugs for $850 million upfront.
Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for …
WEB1 day ago · Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment of $850 million.
Regor Enters into a Definitive Purchase Agreement for ... - BioSpace
WEB1 day ago · Genentech will acquire Regor’s next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones.
Genentech To Acquire Portfolio Of Next-generation CDK Inhibitors …
WEB1 day ago · (RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK...
- Some results have been removed